Literature DB >> 17522386

Clinicopathologic correlation in PGRN mutations.

S Davion1, N Johnson, S Weintraub, M-M Mesulam, A Engberg, M Mishra, M Baker, J Adamson, M Hutton, R Rademakers, E H Bigio.   

Abstract

BACKGROUND: Frontotemporal dementia (FTD) has been linked to the microtubule associated protein tau (MAPT) gene region of chromosome 17. However, many chromosome-17 linked FTLDs do not have MAPT mutations or tau protein deposits, but have ubiquitin positive, tau and alpha-synuclein negative inclusions. Mutations in the progranulin (PGRN) gene, located 1.7 Mb from MAPT at 17q21.31, were recently discovered in some of these individuals. The pathologic phenotype in all cases has thus far included ubiquitinated neuronal intranuclear inclusions (NIIs) and neuronal cytoplasmic inclusions (NCIs).
METHODS: PGRN mutation analysis was performed in 12 individuals. Informed consent was obtained from next of kin under an IRB-approved protocol. We compared clinical and pathologic findings in those cases with and without PGRN mutations.
RESULTS: PGRN mutations were found in four patients, two with clinical FTD and a positive family history, and two with clinical primary progressive aphasia (PPA), one with and one without a family history. All four cases with, and five of eight cases without, PGRN mutations had ubiquitinated NCIs and NIIs. Brains of individuals with PGRN mutations are associated with more frequent frontal NCIs and dystrophic neurites, less frequent dentate gyrus NCIs, and more frequent striatal NIIs than FTLD-U cases without PGRN mutations.
CONCLUSION: PGRN mutations at 17q21 may occur in apparently sporadic frontotemporal lobar dementia with ubiquitinated inclusions cases and in cases presenting with either primary progressive aphasia or the behavioral variant of frontotemporal dementia. Some cases without PGRN mutations also have ubiquitinated neuronal intranuclear inclusions. Clinicopathologic differences are observed among individuals with and without PGRN mutations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17522386      PMCID: PMC3545400          DOI: 10.1212/01.wnl.0000267701.58488.69

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  27 in total

1.  Re: UPDRS: Status and recommendations.

Authors:  Christopher Goetz
Journal:  Mov Disord       Date:  2004-05       Impact factor: 10.338

Review 2.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.

Authors:  D Neary; J S Snowden; L Gustafson; U Passant; D Stuss; S Black; M Freedman; A Kertesz; P H Robert; M Albert; K Boone; B L Miller; J Cummings; D F Benson
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

3.  The National Alzheimer's Coordinating Center (NACC) Database: an Alzheimer disease database.

Authors:  Duane L Beekly; Erin M Ramos; Gerald van Belle; Woodrow Deitrich; Amber D Clark; Mary E Jacka; Walter A Kukull
Journal:  Alzheimer Dis Assoc Disord       Date:  2004 Oct-Dec       Impact factor: 2.703

4.  Antemortem diagnosis of frontotemporal lobar degeneration.

Authors:  David S Knopman; Bradley F Boeve; Joseph E Parisi; Dennis W Dickson; Glenn E Smith; Robert J Ivnik; Keith A Josephs; Ronald C Petersen
Journal:  Ann Neurol       Date:  2005-04       Impact factor: 10.422

5.  Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease?

Authors:  S Bozeat; C A Gregory; M A Ralph; J R Hodges
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-08       Impact factor: 10.154

6.  Clinical and pathological evidence for a frontal variant of Alzheimer disease.

Authors:  J K Johnson; E Head; R Kim; A Starr; C W Cotman
Journal:  Arch Neurol       Date:  1999-10

7.  Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory.

Authors:  D I Kaufer; J L Cummings; P Ketchel; V Smith; A MacMillan; T Shelley; O L Lopez; S T DeKosky
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2000       Impact factor: 2.198

Review 8.  Frontotemporal dementia: implications for understanding Alzheimer disease.

Authors:  Michel Goedert; Bernardino Ghetti; Maria Grazia Spillantini
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

9.  Similar early clinical presentations in familial and non-familial frontotemporal dementia.

Authors:  O Piguet; W S Brooks; G M Halliday; P R Schofield; P M Stanford; J B J Kwok; M-G Spillantini; D Yancopoulou; P J Nestor; G A Broe; J R Hodges
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-12       Impact factor: 10.154

10.  The prevalence of frontotemporal dementia.

Authors:  E Ratnavalli; C Brayne; K Dawson; J R Hodges
Journal:  Neurology       Date:  2002-06-11       Impact factor: 9.910

View more
  19 in total

Review 1.  Update on recent molecular and genetic advances in frontotemporal lobar degeneration.

Authors:  Eileen H Bigio
Journal:  J Neuropathol Exp Neurol       Date:  2008-07       Impact factor: 3.685

2.  TDP-43 variants of frontotemporal lobar degeneration.

Authors:  Eileen H Bigio
Journal:  J Mol Neurosci       Date:  2011-05-24       Impact factor: 3.444

Review 3.  The non-fluent/agrammatic variant of primary progressive aphasia.

Authors:  Murray Grossman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

4.  Comparative quantitative study of 'signature' pathological lesions in the hippocampus and adjacent gyri of 12 neurodegenerative disorders.

Authors:  Richard A Armstrong; Nigel J Cairns
Journal:  J Neural Transm (Vienna)       Date:  2015-05-01       Impact factor: 3.575

5.  The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration.

Authors:  Chang-En Yu; Thomas D Bird; Lynn M Bekris; Thomas J Montine; James B Leverenz; Ellen Steinbart; Nichole M Galloway; Howard Feldman; Randall Woltjer; Carol A Miller; Elisabeth McCarty Wood; Murray Grossman; Leo McCluskey; Christopher M Clark; Manuela Neumann; Adrian Danek; Douglas R Galasko; Steven E Arnold; Alice Chen-Plotkin; Anna Karydas; Bruce L Miller; John Q Trojanowski; Virginia M-Y Lee; Gerard D Schellenberg; Vivianna M Van Deerlin
Journal:  Arch Neurol       Date:  2010-02

6.  TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia.

Authors:  J D Rohrer; F Geser; J Zhou; E D Gennatas; M Sidhu; J Q Trojanowski; S J Dearmond; B L Miller; W W Seeley
Journal:  Neurology       Date:  2010-12-14       Impact factor: 9.910

Review 7.  Parkinsonism, movement disorders and genetics in frontotemporal dementia.

Authors:  José Fidel Baizabal-Carvallo; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2016-02-19       Impact factor: 42.937

8.  Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis.

Authors:  Richard A Armstrong; William Ellis; Ronald L Hamilton; Ian R A Mackenzie; John Hedreen; Marla Gearing; Thomas Montine; Jean-Paul Vonsattel; Elizabeth Head; Andrew P Lieberman; Nigel J Cairns
Journal:  J Neural Transm (Vienna)       Date:  2009-12-10       Impact factor: 3.575

9.  TARDBP 3'-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy.

Authors:  Michael A Gitcho; Eileen H Bigio; Manjari Mishra; Nancy Johnson; Sandra Weintraub; Marsel Mesulam; Rosa Rademakers; Sumi Chakraverty; Carlos Cruchaga; John C Morris; Alison M Goate; Nigel J Cairns
Journal:  Acta Neuropathol       Date:  2009-07-18       Impact factor: 17.088

Review 10.  ALS and FTLD: two faces of TDP-43 proteinopathy.

Authors:  R M Liscic; L T Grinberg; J Zidar; M A Gitcho; N J Cairns
Journal:  Eur J Neurol       Date:  2008-08       Impact factor: 6.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.